PMID- 26464671
OWN - NLM
STAT- MEDLINE
DCOM- 20160810
LR  - 20181113
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 8
IP  - 8
DP  - 2015
TI  - Expression of paxillin in laryngeal squamous cell carcinoma and its prognostic 
      value.
PG  - 9232-9
AB  - Paxillin (PXN) gene has been reported to act as an oncogene in many malignancies 
      and play important roles in the development of human carcinomas. However, the 
      relationship between the expression of PXN and clinicopathological 
      characteristics in human laryngeal carcinoma remains unclear. This study aimed to 
      examine the expression of PXN, and to evaluate the clinical significance of its 
      expression in human laryngeal squamous cell carcinoma (LSCC). Real-time 
      quantitative PCR (qRT-PCR), Western blotting and immunohistochemistry were 
      performed to analyze the expression of PXN in LSCC tissues and corresponding 
      paracancerous normal tissues. Kaplan-Meier survival and Cox regression analyses 
      were performed to evaluate the prognosis of patients with LSCC. The expression of 
      PXN was significantly higher in LSCC than in matched paracancerous normal 
      tissues. Immunohistochemical analysis was performed in human LSCC samples and the 
      data were correlated with clinicopathologic features. Levels of PXN in LSCC were 
      related to histopathological grade (P = 0.016), Lymph node metastasis (P = 0.029) 
      and TNM stage (P < 0.001). Kaplan-Meier analysis revealed that survival curves of 
      the overall survival of patients with high PXN expression was significantly worse 
      than that of low PXN expression (P = 0.035). Cox regression analysis revealed 
      that PXN expression level was an independent prognostic factor of the overall 
      survival rate of patients with LSCC (P = 0.002). These findings suggest that PXN 
      expression has potential use as a novel biomarker of LSCC patients and may serve 
      as an independent predictive factor for prognosis of LSCC patients.
FAU - Li, Lianqing
AU  - Li L
AD  - Medical College of Qingdao University Qingdao 266000, Shandong Province, People's 
      Republic of China ; Department of Otolaryngology, The People's Hospital of 
      Liaocheng Liaocheng 252000, Shandong Province, People's Republic of China.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Otolaryngology, The People's Hospital of Liaocheng Liaocheng 
      252000, Shandong Province, People's Republic of China.
FAU - Gao, Lei
AU  - Gao L
AD  - Department of Hematology, The People's Hospital of Liaocheng Liaocheng 252000, 
      Shandong Province, People's Republic of China.
FAU - Gong, Lili
AU  - Gong L
AD  - Department of Otolaryngology, The People's Hospital of Liaocheng Liaocheng 
      252000, Shandong Province, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20150801
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Paxillin)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Carcinoma, Squamous Cell/*diagnosis/metabolism/mortality/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/*diagnosis/metabolism/mortality/pathology
MH  - Lymphatic Metastasis/*diagnosis/pathology
MH  - Male
MH  - Middle Aged
MH  - Paxillin/*metabolism
MH  - Prognosis
MH  - Survival Rate
PMC - PMC4583903
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma
OT  - paxillin
OT  - prognosis
EDAT- 2015/10/16 06:00
MHDA- 2016/08/11 06:00
PMCR- 2015/08/01
CRDT- 2015/10/15 06:00
PHST- 2015/05/18 00:00 [received]
PHST- 2015/06/27 00:00 [accepted]
PHST- 2015/10/15 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/08/11 06:00 [medline]
PHST- 2015/08/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2015 Aug 1;8(8):9232-9. eCollection 2015.